Mura, 1,054 patient aspirin late treatment PSM study: 15% lower mortality [p=0.08] https://c19p.org/mura
copied to clipboard
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients
et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (preprint 3/31/2021)
PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combination of both.
|
risk of death, 15.4% lower, RR 0.85, p = 0.08, treatment 527, control 527, odds ratio converted to relative risk, aspirin only, control prevalence approximated with treatment prevalence, propensity score matching.
|
|
risk of death, 37.3% lower, RR 0.63, p = 0.001, treatment 305, control 305, odds ratio converted to relative risk, famotidine and aspirin, control prevalence approximated with treatment prevalence, propensity score matching.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mura et al., 3/31/2021, retrospective, database analysis, multiple countries, multiple regions, peer-reviewed, 6 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.